Granted Patent B2

US 12,624,120 · App. 17/796,416 · Granted May 12, 2026

Inventors: Romesh R. Subramanian (Framingham, MA); Mohammed T. Qatanani (Waltham, MA); Timothy Weeden (Waltham, MA); Cody A. Desjardins (Waltham, MA); Brendan Quinn (Boston, MA)

Assignee: Dyne Therapeutics, Inc.

C07K16/2881A61K47/6849A61K2039/505A61K2039/545C07K2317/55C07K2317/565C07K2317/622C07K2317/92

Abstract

Claims (23)

1 . An antibody that binds to human transferrin receptor (TfR), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and the VL comprise:

(i) a heavy chain complementarity determining region 1 (CDR-H1) as set forth in SEQ ID NO: 1, a heavy chain complementarity determining region 2 (CDR-H2) as set forth in SEQ ID NO: 2, a heavy chain complementarity determining region 3 (CDR-H3) as set forth in SEQ ID NO: 3, a light chain complementarity determining region 1 (CDR-L1) as set forth in SEQ ID NO: 4, a light chain complementarity determining region 2 (CDR-L2) as set forth in SEQ ID NO: 5, and a light chain complementarity determining region 3 (CDR-L3) as set forth in SEQ ID NO: 6; or

(ii) a CDR-H1 as set forth in SEQ ID NO: 7, a CDR-H2 as set forth in SEQ ID NO: 8, a CDR-H3 as set forth in SEQ ID NO: 9, a CDR-L1 as set forth in SEQ ID NO: 10, a CDR-L2 as set forth in SEQ ID NO: 11, and a CDR-L3 as set forth in SEQ ID NO: 6; or

(iii) a CDR-H1 as set forth in SEQ ID NO: 12, a CDR-H2 as set forth in SEQ ID NO:13, a CDR-H3 as set forth in SEQ ID NO: 14, a CDR-L1 as set forth in SEQ ID NO: 15, a CDR-L2 as set forth in SEQ ID NO: 5, and a CDR-L3 as set forth in SEQ ID NO: 16.

2 . The antibody of claim 1 , wherein the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 17, and the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 18.

3 . The antibody of claim 2 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 17, and the VL comprises the amino acid sequence of SEQ ID NO: 18.

4 . The antibody of claim 1 , wherein the antibody is selected from the group consisting of a full-length IgG, a Fab fragment, a F(ab′) fragment, a F(ab′)2 fragment, an scFv, and an Fv.

5 . The antibody of claim 4 , wherein the antibody is an scFv.

6 . The antibody of claim 5 , wherein the scFv comprises the amino acid sequence of SEQ ID NO: 19.

7 . The antibody of claim 5 , wherein the scFv is fused to an Fc.

8 . The antibody of claim 7 , wherein the antibody comprises the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22.

9 . The antibody of claim 4 , wherein the antibody is a full-length IgG.

10 . The antibody of claim 9 , wherein the antibody comprises a heavy chain constant region of isotype IgG1 as set forth in SEQ ID NO: 23 or SEQ ID NO: 24.

11 . The antibody of claim 10 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 26 or SEQ ID NO: 27, and a light chain comprising the amino acid sequence of SEQ ID NO: 28.

12 . The antibody of claim 4 , wherein the antibody is a F(ab′) fragment.

13 . The antibody of claim 12 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 30 and a light chain comprising the amino acid sequence of SEQ ID NO: 28.

14 . The antibody of claim 12 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 28.

15 . The antibody of claim 1 , wherein the antibody comprises a heavy chain comprising an N-terminal pyroglutamate.

16 . The antibody of claim 1 , wherein the antibody binds transferrin receptor 1 (TfR1) with a K D in a range of 10 −11 M to 10 −7 M.

17 . A complex comprising the antibody of claim 1 covalently linked to a molecular payload.

18 . A method of detecting a transferrin receptor in a biological sample, comprising contacting the antibody of claim 1 with the biological sample and measuring binding of the antibody to the biological sample.

19 . A method of delivering a molecular payload to the brain or the muscle of a subject, comprising administering to the subject the complex of claim 17 .

20 . A method of treating a disease, comprising administering to the subject the complex of claim 17 , wherein the molecular payload is a therapeutic agent.

Assignments (2)

Continuity (4)

References Cited (400)